PHOENIX, April 26, 2018 (GLOBE NEWSWIRE) — NSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced a collaboration with the University of California (UC) San Diego School of Medicine’s Center for Medicinal Cannabis Research (CMCR) to study cannabidiol (CBD) as a potential treatment for severe symptoms of autism in pediatric patients.
INSYS has agreed to provide its pharmaceutical-grade CBD oral solution—already under clinical evaluation in company-sponsored trials for treatment of refractory pediatric epilepsies—for this CMCR study, which is scheduled to start in 2019.
“We appreciate the opportunity to partner with UC San Diego’s Center for Medicinal Cannabis Research, which has significantly advanced the field’s basic and clinical science over the past two decades,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “Our common commitment to evaluating the safety and efficacy of pharmaceutical-grade cannabinoids in a
... read more at: https://globenewswire.com/news-release/2018/04/26/1488081/0/en/INSYS-Therapeutics-and-University-of-California-UC-San-Diego-Center-for-Medicinal-Cannabis-Research-to-Collaborate-on-Clinical-Trial.html